China’s Innovent Biologics looks to raise up to $422 million in HK IPO: sources

The Shanghai- and Suzhou-based firm … Innovent plans to use the proceeds from its IPO to fund ongoing and planned clinical trials as well as preparations for registration filings and planned commerc…
( read original story …)


Related Post